Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Benefits of Antioxidative Supplement Twendee X for Mild Cognitive Impairment: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Prospective Interventional Study.
Tadokoro K, Morihara R, Ohta Y, Hishikawa N, Kawano S, Sasaki R, Matsumoto N, Nomura E, Nakano Y, Takahashi Y, Takemoto M, Yamashita T, Ueno S, Wakutani Y, Takao Y, Morimoto N, Kutoku Y, Sunada Y, Taomoto K, Manabe Y, Deguchi K, Higashi Y, Inufusa H, You F, Yoshikawa T, von Greiffenclau MM, Abe K. Tadokoro K, et al. Among authors: higashi y. J Alzheimers Dis. 2019;71(3):1063-1069. doi: 10.3233/JAD-190644. J Alzheimers Dis. 2019. PMID: 31476161 Clinical Trial.
A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology.
Abe K, Shang J, Shi X, Yamashita T, Hishikawa N, Takemoto M, Morihara R, Nakano Y, Ohta Y, Deguchi K, Ikeda M, Ikeda Y, Okamoto K, Shoji M, Takatama M, Kojo M, Kuroda T, Ono K, Kimura N, Matsubara E, Osakada Y, Wakutani Y, Takao Y, Higashi Y, Asada K, Senga T, Lee LJ, Tanaka K. Abe K, et al. Among authors: higashi y. J Alzheimers Dis. 2020;73(1):217-227. doi: 10.3233/JAD-191016. J Alzheimers Dis. 2020. PMID: 31771070 Free PMC article.
Tocilizumab-induced Leukoencephalopathy with a Reversible Clinical Course.
Sasaki R, Hishikawa N, Nomura E, Omote Y, Takemoto M, Yamashita T, Hatanaka N, Higashi Y, Abe K. Sasaki R, et al. Among authors: higashi y. Intern Med. 2020 Nov 15;59(22):2927-2930. doi: 10.2169/internalmedicine.5288-20. Epub 2020 Sep 30. Intern Med. 2020. PMID: 32999229 Free PMC article.
Early detection of cognitive decline in mild cognitive impairment and Alzheimer's disease with a novel eye tracking test.
Tadokoro K, Yamashita T, Fukui Y, Nomura E, Ohta Y, Ueno S, Nishina S, Tsunoda K, Wakutani Y, Takao Y, Miyoshi T, Higashi Y, Osakada Y, Sasaki R, Matsumoto N, Kawahara Y, Omote Y, Takemoto M, Hishikawa N, Morihara R, Abe K. Tadokoro K, et al. Among authors: higashi y. J Neurol Sci. 2021 Aug 15;427:117529. doi: 10.1016/j.jns.2021.117529. Epub 2021 Jun 3. J Neurol Sci. 2021. PMID: 34130064
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors.
Hamakawa Y, Hirahara A, Hayashi A, Ito K, Shinohara H, Shiba A, Higashi Y, Aga M, Miyazaki K, Taniguchi Y, Misumi Y, Agemi Y, Nakamura Y, Shimokawa T, Okamoto H. Hamakawa Y, et al. Among authors: higashi y. BMC Cancer. 2025 Jan 6;25(1):17. doi: 10.1186/s12885-025-13440-5. BMC Cancer. 2025. PMID: 39762819 Free PMC article.
1,460 results